Doctronic: The AI Doctor With a Dirty Secret
$65M in VC cash. 24 million "helped." A chatbot that can be tricked into recommending triple-dose OxyContin. And a formulary of auto-refill drugs that would make any ER doctor's blood run cold.
Welcome to AI Health Uncut, a brutally honest newsletter on AI, innovation, and the state of the healthcare market. If you’d like to sign up to receive issues over email, you can do so here.
Important Disclosure. This publication is written and distributed by an independent journalist. It is protected by the First Amendment to the U.S. Constitution and related principles of free expression. Those protections do not relieve me of the obligation to report accurately, and I take that obligation seriously. I strive to rely on verifiable facts, primary-source documentation, and other evidentiary material concerning companies and individuals. I also seek to present information in good faith and in a manner that is fair and non-misleading.
I am also human, and errors can occur. If a reader or an affected party identifies a specific, material factual inaccuracy, I will promptly review the underlying record. If an error is confirmed, I will correct it and, where appropriate, publish a clarification, correction, retraction, and/or apology. Disagreements over interpretation, opinion, tone, or editorial framing are not the same as factual errors. I stand by my reporting, my research, and my sources absent a demonstrated and material factual mistake.
Yesterday, Doctronic announced a $40M Series B led by Abstract Ventures and Lightspeed Venture Partners. Total raised: $65M in less than a year. The company, which calls itself “the world’s #1 AI Doctor,” is on track for $10M+ in revenue this year, according to STAT News.
But first, I want to take a moment to thank all of my supporters. I’m often very critical of certain things happening in AI and healthcare. But I promise you, it’s only because I genuinely care and want to make things better for all of us. So, thank you for your understanding.
I receive a lot of messages daily, and I always respond promptly to every one of them. Most are incredibly kind and supportive.
I want to highlight one recent message in particular. A student reached out recently asking for full, paywall-free access to my Substack. Of course, I granted it—as I always do.
This brings me to another important message. If you cannot afford this article—perhaps you’re a student or currently between jobs—please reach out. That’s precisely why I created the AI Health Uncut Founding Member Club, currently at 19 and counting. Thanks to generous donations and support from these wonderful individuals, I’m able to provide access to anyone who needs it. By the way, students reach out frequently, and I’m always glad to help.
If you’d like to become a Founding Member of the AI Health Uncut community, you can join through this link. You’ll be making a real impact, helping me continue to challenge the system and push for better outcomes in healthcare through AI, technology, policy, and beyond.
🚨 Another quick announcement:
I will be speaking at the Digital Health and AI Innovation Summit (DHAI) 2026 in Boston on June 8-9. Register here. I’ll be talking about my newly developed methodology for measuring VC skill in picking “generational companies.” It’s based on a unique dataset of around 200 publicly traded health tech companies and around 2,000 investment firms and individuals that invested in them. It’s a massive dataset I tediously built over the past several months. And unlike the Forbes annual ranking, I’m using performance metrics, not some subjective “perception of greatness.” 😉 I’ll explain more about this dataset in future posts. I also plan to offer free access to it for my Founding Members.
OK, back to Doctronic’s mess…
If you only read the press release, it’s a beautiful story. Two co-founders, Matt Pavelle (a tech entrepreneur) and Adam Oskowitz (a UCSF surgeon), building an “AI doctor” that delivers 24/7 care across all 50 states, is piloting autonomous AI prescription renewals in Utah (a world first!), and has “helped” over 24 million people. VCs are lining up. Utah is handing them regulatory waivers. And the fawning media coverage has been relentless.
But here’s what nobody’s telling you about Doctronic:
The “24 million helped” number is a fiction.
The one clinical study backing their entire pitch is an embarrassment to peer review.
Cybersecurity researchers jailbroke their chatbot into providing methamphetamine synthesis instructions — and Doctronic couldn’t be bothered to fix it.
Their drug formulary includes medications that no responsible physician would auto-refill.
They appear to be running a massive SEO slop operation to game Google.
And their own B2B web pages still reference a different company called Docus — as if they forgot to change the name. WTF? 🤷
TL;DR:
1. The “24 Million Helped” Lie: Website Traffic Tells a Very Different Story
2. The 99.2% Study: Peer-Reviewed by... the Company That Wrote It
3. When a Cybersecurity Firm Turned the AI Doctor Into Walter White
4. The Doctronic Formulary Problem: Muscle Relaxants, Promethazine, and Drugs That Should Never Be Auto-Refilled
5. The SEO Slop Factory: 591 Pages of AI-Generated Content to Game Google
6. The Docus Ghost: Who Actually Built This?
7. The FDA Question Nobody Wants to Answer
8. Where Do We Go From Here?
Let’s unravel this mess…
